AS SEEN ON
John Montague is a venture capital and technology attorney who advises founders, investors, and high-growth companies operating in emerging and transformative markets. Through Montague Law, John structures financings, governance systems, cross-border entities, and commercialization strategies for startups and investment platforms at the forefront of artificial intelligence, digital assets, blockchain infrastructure, and other next-generation industries.
His practice combines sophisticated transactional counsel with a deep understanding of evolving markets and innovative business models. John advises clients on venture financings, investor alignment, corporate governance, token and digital-asset frameworks, IP strategy, regulatory positioning, and scalable legal structures that support growth in complex and fast-moving sectors. He is particularly focused on helping clients navigate the legal and strategic challenges that arise at the intersection of innovation, capital formation, and global market expansion.
Before founding Montague Law, John practiced at Troutman Pepper Locke, where he focused on venture capital, private equity, and complex transactional matters. He brings more than a decade of experience advising on transformative financings, digital-asset structures, technology commercialization, and growth-stage corporate development.
John is based in Amelia Island, Florida, and represents clients across the United States and internationally.
At Montague Law, we have over a decade of experience providing regulatory and securities compliance to high-growth companies. Whether you are startup, a Web3 company or protocol, or have assets you are looking to protect, let the experienced attorneys at Montague Law guide you in your ventures.
30 big-law quality startup and business formation documents — from incorporation to investor agreements — free to download and customize.
BROWSE FORMS
Florida caps interest at 18% civil, 25% above the threshold, and 45% criminal. Earnout-style seller notes with kickers can push effective rates over the cap without anyone noticing.
Selling to a public-company buyer triggers an 8-K filing within four business days of closing. Three things to negotiate at the LOI to manage your own disclosure.
CVRs look like earnouts but Delaware treats them differently. The 2024 Alexion/Syntimmune ruling and the resulting $180 million damages award reset the efforts-standard analysis for biopharma deals.
or fill out the form below for a consultation.
"*" indicates required fields